What to do with your Mounjaro pen after each dose

Does the pen need to go back in the fridge after you've used it?

Yes. Between each of the four weekly injections, the Mounjaro KwikPen should be stored in the refrigerator at 2–8°C, away from the freezer compartment and direct cooling elements. Light and heat degrade tirzepatide, so leaving the pen on a windowsill or in a warm bathroom is not safe for the medicine inside.

There is a limited window during which the pen can be kept at room temperature, for example, when travelling or if your fridge is temporarily unavailable. That exact window is stated in the Patient Information Leaflet that comes with your pen, and the Mounjaro SmPC on the eMC carries the full licensed storage detail. The duration varies by formulation, so rely on the leaflet rather than a figure you've seen online. A practical tip: most people keep their pen in the fridge door, tucked away from anything that might knock it, and retrieve it around ten minutes before the injection so it reaches room temperature and feels more comfortable going in.

If you are ever unsure whether a pen has been stored correctly (perhaps it was left out for longer than the leaflet allows) contact your prescriber before using it. A degraded dose is worse than a missed one.

What happens to the needle after each injection?

Remove the needle from the pen immediately after every injection. Leaving a needle attached between doses creates a pathway for air and fluid into the cartridge, which can affect dose accuracy and introduce contamination. It also increases the risk of a needlestick injury when you reach for the pen the following week.

Each used needle goes straight into a sharps container, not into general household waste or the recycling bin. A one-litre sharps bin is adequate for most people using a once-weekly medicine. Your local pharmacy or council waste service can advise on collection. Once the needle is off, replace the outer cap on the pen body and return it to the fridge.

Use a fresh needle for every injection. Reusing needles causes unnecessary discomfort (the tip becomes microscopically blunted after a single use) and raises the risk of blocked delivery and infection at the injection site. The NHS tirzepatide medicines page supports this and gives further practical injection guidance worth reading alongside your leaflet.

How do you know when the pen is finished after the fourth dose?

The Mounjaro KwikPen has a dose counter that decreases with each injection. After the fourth and final dose the counter reaches zero and the mechanism locks, you will feel resistance if you try to press the button again, and no medicine will be delivered. That is intentional, not a fault with the pen.

At that point the entire pen, with its cap on, goes into your sharps container. Do not try to draw the remaining liquid out with a syringe or share a pen between patients, neither is safe or licensed. If you noticed anything unusual during the fourth injection, such as the pen not clicking correctly or the counter not advancing, contact your prescriber or our support team before discarding.

People often ask whether there is any medicine left after the fourth dose. In practice, a small amount of liquid always remains in the reservoir, this is deliberate overfill to ensure the fourth full dose is delivered accurately. You are not losing a dose; it is working exactly as designed. For context on how tirzepatide doses are structured across a treatment course, the guide to the fourth dose specifically goes into more detail on what to expect at that stage.

Are there any side effects that tend to appear shortly after an injection?

Some people notice symptoms in the hours following a dose, nausea, mild indigestion, or a dull headache are among the most commonly reported. These tend to be most noticeable after the first injection or after a dose increase, and if you want to know what to expect early on, our overview of what happens after your first dose walks through the typical pattern in detail. Injecting in the evening can help, since the peak discomfort passes during sleep for many people.

Injection-site reactions (a little redness, itchiness or mild bruising) are also common and usually short-lived. Rotating sites across the abdomen, thigh and upper arm at each weekly injection helps reduce localised reactions. Many patients find it useful to read about how the pen and side effects typically settle after the second dose, as that stage often brings a noticeable shift in how the body responds. For a fuller picture of how the body typically responds, the page on heart rate changes with Mounjaro covers one specific side effect that patients sometimes notice and want to understand better.

Serious reactions are uncommon but require prompt attention. Severe, persistent stomach pain that spreads to the back (with or without vomiting) should not be waited out; it needs same-day medical review. The MHRA highlighted acute pancreatitis as a known but infrequent risk associated with GLP-1 medicines in a Drug Safety Update published in January 2026, and the Yellow Card scheme at yellowcard.mhra.gov.uk is the right place to report any suspected side effect. If you are on treatment through nume and have a concern, our prescribers offer priority aftercare seven days a week, and guidance on what to expect after your third dose may also help you judge whether what you are experiencing is typical at that point in treatment; reach us via the contact page.